Global Blood Therapeutics, Inc. (GBT)
(Delayed Data from NSDQ)
$55.18 USD
+1.34 (2.49%)
Updated May 3, 2019 04:00 PM ET
After-Market: $55.12 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$55.18 USD
+1.34 (2.49%)
Updated May 3, 2019 04:00 PM ET
After-Market: $55.12 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Implied Volatility Surging for Global Blood Therapeutics (GBT) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Global Blood Therapeutics (GBT) stock based on the movements in the options market lately.
Are Options Traders Betting on a Big Move in Global Blood (GBT) Stock?
by Zacks Equity Research
Investors need to pay close attention to Global Blood (GBT) stock based on the movements in the options market lately.
Implied Volatility Surging for Global Blood Therapeutics (GBT) Stock Options
by Zacks Equity Research
Investors in Global Blood Therapeutics (GBT) need to pay close attention to the stock based on moves in the options market lately.
Implied Volatility Surging for Global Blood Therapeutics (GBT) Stock Options
by Zacks Equity Research
Investors in Global Blood Therapeutics (GBT) need to pay close attention to the stock based on moves in the options market lately.
Why Global Blood Therapeutics (GBT) Could Be Positioned for a Slump
by Zacks Equity Research
It seems to be a wise decision for investors to drop Global Blood Therapeutics (GBT) stock considering its negative estimate revision, price depreciation as well as unfavorable Zacks rank.
Company News For Dec 18, 2017
by Zacks Equity Research
Companies In The News are: ADBE,COST,ORCL,GBT
Implied Volatility Surging for Global Blood Therapeutics (GBT) Stock Options
by Zacks Equity Research
Global Blood Therapeutics (GBT) warrants investors' attention based on moves in the options market lately.
5 Top Performing Stocks of the Best ETF of Q1
by Sweta Killa
Inside the top performing stocks of biotech ETF that tops the list of the best performing ETFs of Q1.
Global Blood Therapeutics (GBT) in Focus: Stock Jumps 6.8%
by Zacks Equity Research
Global Blood Therapeutics, Inc. (GBT) saw its shares rise almost 7% in the last trading session.